Other languages Takeda Pharmaceutical Company Limited Börse Stuttgart

Equities

TKDA

US8740602052

Market Closed - Börse Stuttgart Other stock markets 02:16:36 2024-06-24 EDT			Pre-market 01:32:02
11.7 ^EUR	+0.86%		12	+2.56%

06-24	Hutchmed China notes Takeda obtains EU approval for Fruzaqla	AN
06-24	Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Hutchmed China notes Takeda obtains EU approval for Fruzaqla	06-24
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	06-24
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare	06-24
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts	06-24
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)	06-23
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	06-22
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	06-21
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	06-21
Les sorcières épouvantent l'IA	06-21
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	06-21
En Direct des Marchés : LVMH, Accor, Alstom, Atos, Casino, Plastivaloire, Boeing, Geberit...	06-21
Borsa di Italia: Le streghe terrorizzano l'AI	06-21
Bolsa de Madrid: Las brujas aterrorizan a la IA	06-21
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	06-21
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	06-20
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India	06-20
Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (PIDC)	06-19
Takeda presenta datos de largo plazo del ensayo clínico de fase 3 ADVANCE-CIDP 3 de HYQVIA® en pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC) en la Reunión Anual de la PNS	06-19
Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung	06-19
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	06-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Takeda Pharmaceutical Company Limited Börse Stuttgart

Equities

TKDA

US8740602052

Other languages

Filters